VEGFA and head and neck squamous cell carcinoma: Hence, our results would support former assumptions, whereas VEGFSerum may depend on the platelet’s ability to release VEGF during coagulation [34,35,36] and may be modified under anti-coagulant treatment, which is often administered to comorbid HNSCC; VEGFPlasma may reflect the level of circulating VEGF more accurately [7], thereby, more reliably, representing the pre-therapeutic angiogenetic pressure caused by the malignancy.